We're Here to Help Mitigate the Impacts of COVID-19

 Free up critical resources with Steripath

As the pressure on emergency departments and hospital resources due to COVID-19 continues to rise, accurate diagnostic testing to confirm, or rule out, sepsis is more important now than ever. Steripath Gen2 delivers (up to) a 97% positive predictive value for blood cultures, a 60% improvement over standard method.1,2 Improving your testing accuracy can reduce the burden on our healthcare system at this critical time.

Free-Up Bed Space

Adoption of Steripath can shorten length of stay by an average of 2 to 2.4 days3,4, opening up space for patients who need it most.

Increase Lab & PCR Capacity

Analysis of false positive blood cultures takes up critical lab and PCR processing capacity. Reduce this unnecessary testing burden and free up your resources.

Maximize Scarce Resources

False-positive results for sepsis lead to many wasted resources including PPE, provider time & focus, testing supplies & antibiotics.

COVID-19 Support Program

We're Here to Help!

Magnolia Medical is committed to helping ease the burden that the COVID-19 pandemic is placing on hospital staff and resources. To help, we are offering complimentary services and initial product during this time of crisis. Adopt Steripath now to immediately benefit from improved sepsis testing accuracy.

Current Customers will receive:

Expedited hospital-wide expansion 

Complimentary initial training product

Clinical Performance Guarantee

New Customers will receive:

RN led in-person and online training program

Complimentary initial product

Clinical Performance Guarantee

Steripath Gen2 Logo Reverse

Adopt the only FDA-cleared device indicated to reduce blood culture contamination5 

Thank you! We will be in contact with you shortly. In the meantime, please visit www.magnolia-medical.com to learn more about Steripath®.

All the best,
Magnolia Medical

We're sorry. An error occurred during the submission of this form. Please try submitting the form again.


  1. Zwang, O., et al. Journal of Hospital Medicine (2006)
  2. M. Rupp, et al; Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device. Clinical Infectious Diseases (August 2017)
  3. Geisler BP et al., Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes, Journal of Hospital Infection, https://doi.org/10.1016/j.jhin.2019.03.012

  4. Skoglund E, Dempsey CJ, Chen H, Garey KW. 2019. Estimated clinical and economic impact through use of a novel blood collection device to reduce blood culture contamination in the emergency department: a cost-benefit analysis. J Clin Microbiol 57:e01015-18. https://doi.org/10.1128/JCM .01015-18.

  5. Indicated to reduce blood culture contamination when contaminants are present, compared to standard method controls without diversion.